Posted on August 19, 2011 by Sitemaster
The value of low-dose diethylstilbestrol (DES) in the management of men with advanced and castration-resistant prostate cancer (CRPC) comes up as a regular topic for review and discussion. Before development of the LHRH agonists, DES was the most commonly used — and much studied — drug for the treatment of advanced (metastatic) prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant prostate cancer, CRPC, DES, diethylstilbestrol | 3 Comments »
Posted on April 30, 2011 by Sitemaster
An article from Thursday’s “The Pink Sheet”, posted on the OncologySTAT web site today, is already asking questions about the potential future use of abiraterone acetate in patients with non-metastatic, castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, cabazitaxel, castration-resistant prostate cancer, CRPC | 12 Comments »
Posted on August 8, 2010 by Sitemaster
Figitumumab (also known as CP-751,871) is a fully humanized monoclonal antibody designed to target the insulin-like growth factor type 1 receptor (IGF-IR). Data are now available from a very early-stage trial of figitumumab in combination with docetaxel in the treatment of patients with late-stage solid tumors — including castration-resiatant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development | Tagged: 871, castration-resistant prostate cancer, CP-751, CRPC, figitumumab | Leave a comment »
Posted on June 5, 2010 by Sitemaster
One of the really “hot” pieces of news from ASCO today was the result of a Phase III clinical trial of ipilimumab in a form of metastatic skin cancer called melanoma. This is (perhaps) very important for prostate cancer patients. … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, ipilimumab | Leave a comment »
Posted on May 21, 2010 by Sitemaster
We commented earlier today on the positive data about tasquinimod that will be presented at the ASCO annual meeting. Negative data will unfortunately be presented on other drugs, but not everything is doom and gloom. … READ MORE …
Filed under: Drugs in development, Management | Tagged: abiraterone, bevacizumab, cabazitaxel, castration-resistant prostate cancer, CRPC, docetaxel, eribulin, metastatic | Leave a comment »
Posted on May 21, 2010 by Sitemaster
Looking quickly through the abstracts of presentations on investigational therapies to be presented at the annual meeting of the American Society for Clinical Oncology (ASCO), starting on June 4 in Chicago, one particular paper stood out — a Phase II trial of tasquinimod. … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, metastatic, tasquinimod | Leave a comment »
Posted on May 1, 2010 by Sitemaster
Today’s news reports include comments on studies dealing with:
- A compound panel of markers for predicting risk for prostate cancer
- Open vs. robot-assisted radical prostatectomy: urologists’ perceptions
- Clinically relevant quality of life assessment after first-line therapy
- A compound panel of markers for predicting overall survival of patients with CRPC … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: castration-resistant prostate cancer, CRPC, kallikrein, open, prognosis, prostatectomy, quality of life, RALP, risk, robot-assisted, survival | Leave a comment »
Posted on April 29, 2010 by Sitemaster
Docetaxel + prednisone is the current standard treatment for men with castration-resistant prostate cancer (CRPC). However, the survival benefit of this form of treatment is small compared to older forms of therapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant prostate cancer, combination, CRPC, docetaxel, ketoconazole | Leave a comment »
Posted on April 28, 2010 by Sitemaster
Evidence continues to accumulate that serum levels of C-reactive protein (CRP) may have value as a prognostic marker for survival in men with very early and very late-stage forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: C-reactive protein, castration-resistant prostate cancer, CRP, CRPC, Diagnosis, localized, prognosis, risk | 1 Comment »
Posted on April 19, 2010 by Sitemaster
Straight from a “late-breaking poster” at the annual meeting of the Association for the Advancement of Cancer Research going on in Washington, DC, comes data about BPX-101 — another dendritic cell-based immunotherapeutic “vaccine” for the possible treatment of late-stage prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: BPX-103, castration-resistant prostate cancer, CRPC, vaccine | 3 Comments »
Posted on March 12, 2010 by Sitemaster
The pharmaceutical company Roche announced this morning that the combination of bevacizumab (Avastin) with docetaxel and prednisone does not extend the overall survival of men with hormone-refractory prostate cancer (HRPC) compared to docetaxel + prednisone alone. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: Avastin, bevacizumab, castration-resistant prostate cancer, CRPC, HRPC, survival, trial | Leave a comment »
Posted on February 18, 2010 by Sitemaster
On Tuesday this week, three papers about abiraterone acetate were published in the on-line version of the Journal of Clinical Oncology. These articles are reports of data previously presented at various clinical/scientific meetings, but at least they are now available in a peer-reviewed journal. … READ MORE …
Filed under: Drugs in development, Uncategorized | Tagged: abiraterone acetate, castration-resistant prostate cancer, CRPC | 14 Comments »
Posted on January 26, 2010 by Sitemaster
According to a story on ScienceDaily today, investigators are continuing to plan for a Phase III clinical trial of PROSTVAC-VF — a poxvirus-based prostate cancer “vaccine” — in men with castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, immunobiologics, PROSTVAC-VF, vaccine | 14 Comments »
Posted on January 16, 2010 by Sitemaster
Spinal cord compression (SCC) is a major complication of metastatic castration-resistant prostate cancer (CRPC) and the onset of SCC is associated with potentially severe neurological problems. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant prostate cancer, CRPC, magnetic resonance imaging, spinal cord compression, spinal MRI | 2 Comments »
Posted on November 11, 2009 by Sitemaster
A new, oral drug called TOK-001, made by Tokai Pharmaceuticals, will shortly enter Phase I/II clinical trials for the treatment of castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, TOK-001 | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 